Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
24.68
+0.21 (0.86%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Pacira BioSciences Revenue
In the year 2024, Pacira BioSciences had annual revenue of $700.97M with 3.85% growth. Pacira BioSciences had revenue of $187.25M in the quarter ending December 31, 2024, with 3.32% growth.
Revenue (ttm)
$700.97M
Revenue Growth
+3.85%
P/S Ratio
1.63
Revenue / Employee
$887,299
Employees
790
Market Cap
1.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PCRX News
- 3 days ago - Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders - GlobeNewsWire
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - Accesswire
- 9 days ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - Accesswire
- 11 days ago - Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act - Seeking Alpha
- 12 days ago - Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps - Benzinga
- 12 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - Accesswire
- 13 days ago - Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL - GlobeNewsWire